Sino Biopharmaceutical

Sino Biopharmaceutical achieved strong financial results in 2024, with revenue reaching RMB 28.87B ($4.0B), a 10.2% YoY increase. Profit rose by 24.9% to RMB 6.36B, while profit attributable to owners increased by 50.1% to RMB 3.50B. The company's innovative products generated RMB 12.06B, representing 41.8% of total revenue and a 21.9% YoY increase. With an R&D investment of 17.6% of revenue, Sino Biopharmaceutical maintains a robust pipeline of products across key therapeutic areas.